ATE184191T3 - Pharmazeutische formulierung - Google Patents

Pharmazeutische formulierung Download PDF

Info

Publication number
ATE184191T3
ATE184191T3 AT94901148T AT94901148T ATE184191T3 AT E184191 T3 ATE184191 T3 AT E184191T3 AT 94901148 T AT94901148 T AT 94901148T AT 94901148 T AT94901148 T AT 94901148T AT E184191 T3 ATE184191 T3 AT E184191T3
Authority
AT
Austria
Prior art keywords
pct
date
pharmaceutical formulation
sec
active agent
Prior art date
Application number
AT94901148T
Other languages
German (de)
English (en)
Inventor
Christer Nystroem
Lennart Paalzow
Sten-Magnus Aquilonius
Original Assignee
Neopharma Production Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharma Production Ab filed Critical Neopharma Production Ab
Publication of ATE184191T3 publication Critical patent/ATE184191T3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94901148T 1992-11-30 1993-11-29 Pharmazeutische formulierung ATE184191T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system

Publications (1)

Publication Number Publication Date
ATE184191T3 true ATE184191T3 (de) 1999-09-15

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94901148T ATE184191T3 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung

Country Status (15)

Country Link
US (1) US5635213A (esLanguage)
EP (1) EP0670713B3 (esLanguage)
JP (1) JP3661703B2 (esLanguage)
AT (1) ATE184191T3 (esLanguage)
AU (1) AU688290B2 (esLanguage)
CA (1) CA2150464C (esLanguage)
DE (2) DE69326350T3 (esLanguage)
DK (1) DK0670713T3 (esLanguage)
ES (1) ES2137350T7 (esLanguage)
FR (1) FR04C0024I2 (esLanguage)
GR (1) GR3031988T3 (esLanguage)
NL (1) NL300169I1 (esLanguage)
NZ (1) NZ258276A (esLanguage)
SE (1) SE9203594D0 (esLanguage)
WO (1) WO1994012153A1 (esLanguage)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
CA2653683A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
EP4356907A1 (en) 2014-09-04 2024-04-24 LobSor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3487479A1 (en) * 2016-07-20 2019-05-29 AbbVie Inc. Levodopa and carbidopa intestinal gel and methods of use
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
ES3053690T3 (en) 2018-03-23 2026-01-23 Lobsor Pharmaceuticals Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
UY38473A (es) 2018-11-15 2020-06-30 Abbvie Inc Formulaciones farmacéuticas para una administración subcutánea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
AU688290B2 (en) 1998-03-12
FR04C0024I1 (esLanguage) 2004-03-12
DE122005000021I1 (de) 2006-02-23
DK0670713T3 (da) 2000-03-20
EP0670713A1 (en) 1995-09-13
EP0670713B3 (en) 2016-10-05
EP0670713B1 (en) 1999-09-08
US5635213A (en) 1997-06-03
DE69326350T3 (de) 2018-01-11
JPH08504764A (ja) 1996-05-21
DE69326350D1 (de) 1999-10-14
NL300169I1 (nl) 2005-03-01
GR3031988T3 (en) 2000-03-31
FR04C0024I2 (esLanguage) 2010-12-31
CA2150464C (en) 2002-02-05
JP3661703B2 (ja) 2005-06-22
SE9203594D0 (sv) 1992-11-30
DE69326350T2 (de) 2000-01-27
WO1994012153A1 (en) 1994-06-09
NZ258276A (en) 1996-09-25
CA2150464A1 (en) 1994-06-09
ES2137350T7 (es) 2017-11-13
ES2137350T3 (es) 1999-12-16
AU5583694A (en) 1994-06-22

Similar Documents

Publication Publication Date Title
DE69326350D1 (de) Pharmazeutische formulierung
DE69305328D1 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
ITMI922192A1 (it) Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
ES2052016T3 (es) Composicion emulsionada.
TW347339B (en) Oral delivery of discrete units
ATE333867T1 (de) Emulgierte arzneistoffabgabesysteme
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
ATE241990T1 (de) 3-beta-hydroxylierte natürliche steroidderivate enthaltende arzneimittelzusammensetzungen und ihre verwendung
NO954320L (no) Lyosfærer omfattende gonadotropin
MY101791A (en) New benzimidazole derivatives
ATE162725T1 (de) Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
DE69106501D1 (de) Osmotisches dosiersystem zur verabreichung von flüssigen arzneimitteln.
DE69803940D1 (de) Ophthalmische zusammensetzungen mit verlängerte freisetzung enthaltend im wasser lösliche arzneistoffe
ATE192921T1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
DE59505047D1 (de) Versprühbare filmbildende wirkstoffabgabesysteme zur anwendung an pflanzen
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
ATE167800T1 (de) Polymeres arzneimittelabgabesystem
HUT51269A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same
KR950703931A (ko) 캡슐화된 부형제를 갖는 전달장치(Delivery device having encapsulated excipinents)
SE8305485D0 (sv) Galenic compositions comprising calcitonin and their use
ITMI931326A1 (it) Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
TR200200841T2 (tr) Mukozaya uygulama için, siklesonid içeren farmasötik kompozisyon
ATE175867T1 (de) Ophthalmologische zubereitungen
MY102411A (en) Nasal solutions
CA2185883A1 (en) The use of dimeticone as a transport and carrier system and/or drug delivery system